Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan

NCT07755826 · clinicaltrials.gov ↗

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

NTRK Fusion-positive Solid Tumors

Interventions

DRUG: Repotrectinib

Sponsor

Bristol-Myers Squibb